305 related articles for article (PubMed ID: 28425639)
1. Designing dual inhibitors of Mdm2/MdmX: Unexpected coupling of water with gatekeeper Y100/99.
Lee XA; Verma C; Sim AYL
Proteins; 2017 Aug; 85(8):1493-1506. PubMed ID: 28425639
[TBL] [Abstract][Full Text] [Related]
2. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
3. Targeting the conformational transitions of MDM2 and MDMX: insights into key residues affecting p53 recognition.
Carotti A; Macchiarulo A; Giacchè N; Pellicciari R
Proteins; 2009 Nov; 77(3):524-35. PubMed ID: 19507240
[TBL] [Abstract][Full Text] [Related]
4. Probing Origin of Binding Difference of inhibitors to MDM2 and MDMX by Polarizable Molecular Dynamics Simulation and QM/MM-GBSA Calculation.
Chen J; Wang J; Zhang Q; Chen K; Zhu W
Sci Rep; 2015 Nov; 5():17421. PubMed ID: 26616018
[TBL] [Abstract][Full Text] [Related]
5. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay.
Golestanian S; Sharifi A; Popowicz GM; Azizian H; Foroumadi A; Szwagierczak A; Holak TA; Amanlou M
Life Sci; 2016 Jan; 145():240-6. PubMed ID: 26746660
[TBL] [Abstract][Full Text] [Related]
7. Molecular basis for the inhibition of p53 by Mdmx.
Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
[TBL] [Abstract][Full Text] [Related]
8. Molecular modeling and molecular dynamics simulation studies on pyrrolopyrimidine-based α-helix mimetic as dual inhibitors of MDM2 and MDMX.
Lu SY; Jiang YJ; Zou JW; Wu TX
J Mol Graph Model; 2011 Sep; 30():167-78. PubMed ID: 21820342
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
[TBL] [Abstract][Full Text] [Related]
10. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.
Qin L; Yang F; Zhou C; Chen Y; Zhang H; Su Z
J Am Chem Soc; 2014 Dec; 136(52):18023-33. PubMed ID: 25453499
[TBL] [Abstract][Full Text] [Related]
11. Computational studies of difference in binding modes of peptide and non-peptide inhibitors to MDM2/MDMX based on molecular dynamics simulations.
Chen J; Zhang D; Zhang Y; Li G
Int J Mol Sci; 2012; 13(2):2176-2195. PubMed ID: 22408446
[TBL] [Abstract][Full Text] [Related]
12. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.
ElSawy KM; Verma CS; Joseph TL; Lane DP; Twarock R; Caves LS
Cell Cycle; 2013 Feb; 12(3):394-404. PubMed ID: 23324352
[TBL] [Abstract][Full Text] [Related]
13. Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach.
Zaytsev A; Dodd B; Magnani M; Ghiron C; Golding BT; Griffin RJ; Liu J; Lu X; Micco I; Newell DR; Padova A; Robertson G; Lunec J; Hardcastle IR
Chem Biol Drug Des; 2015 Aug; 86(2):180-9. PubMed ID: 25388787
[TBL] [Abstract][Full Text] [Related]
14. A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors.
Chen R; Zhou J; Qin L; Chen Y; Huang Y; Liu H; Su Z
Biochemistry; 2017 Jun; 56(25):3273-3282. PubMed ID: 28581721
[TBL] [Abstract][Full Text] [Related]
15. Development of cell-penetrating peptide-based drug leads to inhibit MDMX:p53 and MDM2:p53 interactions.
Philippe G; Huang YH; Cheneval O; Lawrence N; Zhang Z; Fairlie DP; Craik DJ; de Araujo AD; Henriques ST
Biopolymers; 2016 Nov; 106(6):853-863. PubMed ID: 27287767
[TBL] [Abstract][Full Text] [Related]
16. Modulation of p53 binding to MDM2: computational studies reveal important roles of Tyr100.
Dastidar SG; Lane DP; Verma CS
BMC Bioinformatics; 2009 Dec; 10 Suppl 15(Suppl 15):S6. PubMed ID: 19958516
[TBL] [Abstract][Full Text] [Related]
17. An Update on MDMX and Dual MDM2/X Inhibitors.
Espadinha M; Barcherini V; Lopes EA; Santos MMM
Curr Top Med Chem; 2018; 18(8):647-660. PubMed ID: 29866007
[TBL] [Abstract][Full Text] [Related]
18. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
[TBL] [Abstract][Full Text] [Related]
19. Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.
Barakat K; Mane J; Friesen D; Tuszynski J
J Mol Graph Model; 2010 Feb; 28(6):555-68. PubMed ID: 20056466
[TBL] [Abstract][Full Text] [Related]
20. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
